Page 17 | Certara

Poster

QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments

Discover how Certara uses QSP modeling to advance the development of KK2269, a bispecific antibody…

CertaraJune 18, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Press Coverage

How is the pharmaceutical industry addressing global health inequities?

Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…

CertaraJune 17, 2025

Poster

A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3

Explore a cutting-edge minimal PBPK/PD oncology mouse model for 212Pb-based Radio-DARPin MP0712, meticulously designed to…

CertaraJune 16, 2025

Blog

How a budget-impact analysis complements cost-effectiveness to present a balanced economic outlook

June 16, 2025 Editor’s note: This is the third of four articles in our series…

Simona ColucciJune 16, 2025

Announcement

Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power

June 16, 2025 RADNOR, PA – June 16, 2025 – Certara, Inc. (Nasdaq: CERT), a…

CertaraJune 16, 2025

Live Events

Certainty Discovery

- Frankfurt, Germany

CertaraJune 14, 2025

Live Events

Certainty EMEA

- Bareclona, Spain

CertaraJune 14, 2025

Announcement

Certara Earns Great Place to Work Certification™ for Fourth Consecutive Year

Certara wins Great Place to Work Certification, with 85% of employees praising workplace culture, innovation,…

CertaraJune 13, 2025

Poster

A Quantitative Systems Pharmacology Model to Investigate the Crucial Role of Epithelial Damage in the Pathogenesis of Inflammatory Bowel Disease

In inflammatory bowel disease (IBD) patients, there is an imbalance between pro- and anti-inflammatory cytokines.…

Danielle PillsburyJune 13, 2025

QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

How is the pharmaceutical industry addressing global health inequities?

A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3

How a budget-impact analysis complements cost-effectiveness to present a balanced economic outlook

Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power

Certainty Discovery

Certainty EMEA

Certara Earns Great Place to Work Certification™ for Fourth Consecutive Year

A Quantitative Systems Pharmacology Model to Investigate the Crucial Role of Epithelial Damage in the Pathogenesis of Inflammatory Bowel Disease

Newsletter sign up

Quick links

Solutions

Contact